Key Points
- CEO insider sale: John Mastrototaro sold 2,514 shares on Jan. 5 at an average of $8.21 for $20,639.94, reducing his holding by about 36% to 4,430 shares.
- Weak fundamentals despite an EPS beat: Movano is a micro‑cap (~$6.2M) with a Q3 EPS of -$4.73 that beat estimates but on just $0.08M of revenue and with extremely negative margins and return on equity.
- Institutional activity but low liquidity: Citadel Advisors disclosed a new stake of 49,262 shares (~5.94%), yet the stock’s tiny market cap and low liquidity mean insider sales and technical moves can have outsized market impact.
Movano Inc. (NASDAQ:MOVE - Get Free Report) CEO John Mastrototaro sold 2,514 shares of the company's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $8.21, for a total value of $20,639.94. Following the sale, the chief executive officer owned 4,430 shares in the company, valued at approximately $36,370.30. This trade represents a 36.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Movano Stock Performance
Shares of MOVE opened at $7.50 on Thursday. The stock has a 50-day simple moving average of $8.75 and a 200-day simple moving average of $7.57. The stock has a market capitalization of $6.23 million, a PE ratio of -0.69 and a beta of 0.79. Movano Inc. has a 1 year low of $4.67 and a 1 year high of $59.90.
Movano (NASDAQ:MOVE - Get Free Report) last released its earnings results on Friday, November 14th. The technology company reported ($4.73) earnings per share for the quarter, topping analysts' consensus estimates of ($7.00) by $2.27. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $3.88 million. Movano had a negative net margin of 3,409.60% and a negative return on equity of 647.91%.
Key Movano News
Here are the key news stories impacting Movano this week:
- Positive Sentiment: Technical breakout: Movano's share price moved above its 200‑day moving average (the stock traded as high as about $8.43), a common momentum signal that can attract short‑term buyers and algorithmic flows. Movano (NASDAQ:MOVE) Share Price Passes Above 200 Day Moving Average – Here’s Why
- Neutral Sentiment: Context on the stock: MOVE is a very small‑cap, low‑liquidity name (market cap shown at roughly $6.2M) with a 50‑day MA near $8.75 and a 200‑day MA near $7.57; its 52‑week range is wide ($4.67–$59.90), so technical moves can be exaggerated. Movano Stock Page
- Negative Sentiment: Insider selling: CEO John Mastrototaro sold 2,514 shares on Jan. 5 at an average of $8.21, cutting his holding by ~36%. Insider sales can be read negatively by the market, especially in a tiny company where insider ownership levels matter for confidence. The SEC filing disclosing the sale is available here. SEC Filing: Ownership
Institutional Investors Weigh In On Movano
A hedge fund recently bought a new stake in Movano stock. Citadel Advisors LLC purchased a new stake in Movano Inc. (NASDAQ:MOVE - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 49,262 shares of the technology company's stock, valued at approximately $28,000. Citadel Advisors LLC owned about 5.94% of Movano at the end of the most recent reporting period. Institutional investors own 16.64% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Movano in a research note on Wednesday, October 8th. Wall Street Zen raised Movano to a "hold" rating in a report on Saturday, December 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Movano presently has a consensus rating of "Sell".
Get Our Latest Stock Analysis on MOVE
Movano Company Profile
(
Get Free Report)
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company's core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano's flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
